Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Pfizer (PFE)

NYSE Health Care Pharmaceuticals S&P 500
$29.39
-0.49 (-1.64%)
Close of Nov 06, 2026 · end-of-day data
Source: Pfizer's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 04, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$52.82B$52.55B$40.83B$40.91B$41.65B$73.64B$91.79B$50.91B$63.63B$62.58B
Cost of revenue$12.32B$11.23B$8.99B$8.05B$8.48B$30.82B$34.34B$24.95B$17.85B$16.07B
Gross profit$40.50B$41.32B$31.84B$32.85B$33.17B$42.81B$57.45B$25.96B$45.78B$46.51B
Research & development$7.89B$7.68B$7.76B$8.38B$8.71B$10.36B$11.43B$10.68B$10.82B$10.44B
Selling, general & admin$14.84B$14.80B$12.61B$12.73B$11.60B$12.70B$13.68B$14.77B$14.73B$13.79B
Interest expense$1.19B$1.27B$1.32B$1.57B$1.45B$1.29B$1.24B$2.21B$3.09B$2.67B
Pre-tax income$8.35B$12.30B$3.59B$11.32B$7.04B$24.31B$34.73B$1.06B$8.02B$7.52B
Income tax$1.12B-$9.05B-$266.00M$583.00M$370.00M$1.85B$3.33B-$1.11B-$28.00M-$266.00M
Net income$7.21B$21.31B$11.15B$16.03B$9.16B$21.98B$31.37B$2.12B$8.03B$7.77B
EPS (basic)$1.18$3.57$1.90$2.88$1.65$3.92$5.59$0.38$1.42$1.37
EPS (diluted)$1.17$3.52$1.87$2.82$1.63$3.85$5.47$0.37$1.41$1.36
Diluted shares6.16B6.06B5.98B5.67B5.63B5.71B5.73B5.71B5.70B5.71B
Gross margin76.7%78.6%78.0%80.3%79.6%58.1%62.6%51.0%71.9%74.3%
Net margin13.7%40.6%27.3%39.2%22.0%29.8%34.2%4.2%12.6%12.4%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$2.60B$1.34B$1.14B$1.12B$1.79B$1.94B$416.00M$2.85B$1.04B$1.14B
Short-term investments$15.26B$18.65B$17.69B$8.53B$10.44B$22.01B$18.74B$4.40B$10.88B$9.18B
Receivables$8.22B$8.22B$8.03B$6.77B$7.91B$11.48B$10.95B$11.57B$11.46B$11.87B
Inventory$6.78B$7.58B$7.51B$7.07B$8.02B$9.06B$8.98B$10.19B$10.85B$10.65B
Total current assets$38.95B$41.14B$49.93B$32.80B$35.07B$59.69B$51.26B$43.33B$50.36B$42.90B
Goodwill$54.45B$55.95B$42.93B$48.18B$49.56B$49.21B$51.38B$67.78B$68.53B$71.26B
Total assets$171.62B$171.80B$159.42B$167.59B$154.23B$181.48B$197.21B$226.50B$213.40B$208.16B
Total current liabilities$31.11B$30.43B$31.86B$37.30B$25.92B$42.67B$42.14B$47.79B$42.99B$36.98B
Short-term debt$10.69B$9.95B$8.83B$16.20B$2.70B$2.24B$2.94B$10.35B$6.95B$3.15B
Long-term debt$31.40B$33.54B$32.91B$35.95B$37.13B$36.20B$32.88B$61.54B$57.41B$61.64B
Total debt$42.09B$43.49B$41.74B$52.15B$39.84B$38.44B$35.83B$71.89B$64.35B$64.80B
Total liabilities$111.78B$100.14B$95.66B$104.15B$90.76B$104.01B$101.29B$137.21B$124.90B$121.39B
Shareholders' equity$59.54B$71.31B$63.41B$63.14B$63.24B$77.20B$95.66B$89.01B$88.20B$86.48B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$16.19B$16.80B$15.83B$12.59B$14.40B$32.58B$29.27B$8.70B$12.74B$11.70B
Capital expenditures$1.82B$1.96B$1.98B$2.05B$2.23B$2.71B$3.24B$3.91B$2.91B$2.63B
Free cash flow$14.37B$14.85B$13.84B$10.54B$12.18B$29.87B$26.03B$4.79B$9.84B$9.07B
Investing cash flow-$7.79B-$4.74B$4.53B-$3.94B-$4.27B-$22.55B-$15.78B-$32.28B$2.65B-$1.35B
Financing cash flow-$9.23B-$13.35B-$20.44B-$8.48B-$9.65B-$9.82B-$14.83B$26.07B-$17.14B-$10.30B
Share buybacks$5.00B$5.00B$12.20B$8.87B$0$0$2.00B$0$0—
Stock-based compensation$691.00M$840.00M$923.00M$687.00M$755.00M$1.18B$872.00M$525.00M$877.00M$799.00M
Depreciation & amortization$5.76B$6.27B$6.38B$5.75B$4.68B$5.19B$5.06B$6.29B$7.01B$6.59B

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.